Compare ONC & CARR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ONC | CARR |
|---|---|---|
| Founded | 2010 | 2019 |
| Country | Switzerland | United States |
| Employees | 12000 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.6B | 44.7B |
| IPO Year | 2015 | 2020 |
| Metric | ONC | CARR |
|---|---|---|
| Price | $416.47 | $54.28 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 27 | 26 |
| Target Price | ★ $465.00 | $68.70 |
| AVG Volume (30 Days) | 442.0K | ★ 6.4M |
| Earning Date | 11-05-2026 | 10-29-2026 |
| Dividend Yield | N/A | ★ 1.77% |
| EPS Growth | ★ 140.43 | N/A |
| EPS | ★ 0.56 | N/A |
| Revenue | $238,387,000.00 | ★ $21,747,000,000.00 |
| Revenue This Year | $29.05 | $9.50 |
| Revenue Next Year | $15.06 | $6.25 |
| P/E Ratio | $743.85 | ★ N/A |
| Revenue Growth | ★ 22179.16 | N/A |
| 52 Week Low | $253.95 | $50.24 |
| 52 Week High | $424.73 | $76.76 |
| Indicator | ONC | CARR |
|---|---|---|
| Relative Strength Index (RSI) | 67.27 | 45.64 |
| Support Level | $341.67 | $53.91 |
| Resistance Level | N/A | $57.16 |
| Average True Range (ATR) | 10.70 | 1.77 |
| MACD | 4.37 | -0.05 |
| Stochastic Oscillator | 88.77 | 32.01 |
Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of Non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up for 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has a global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes with AbbVie and AstraZeneca mainly. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.
Carrier Global, spun out of United Technologies in 2020, manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its flagship Carrier brand, as well as Bryant, Payne, Heil, and others across various price points. In 2024, Carrier acquired Viessmann Climate Solutions to expand its footprint in Europe with heat pumps, boilers, and solar PV equipment. Proceeds from the sale of Carrier's fire and security (Honeywell) and commercial refrigeration (Haier) businesses reduced debt and focused the company on global HVAC and refrigeration solutions. Carrier generates 75% of sales from equipment and 25% from parts and services. The company derives 50% of revenue from the US, 30% from Europe, and 20% from the Asia-Pacific region.